Step 1 topics → Hematology and Oncology → Hairy Cell Leukemia

Hairy Cell Leukemia

USMLE Step 1 trap: Incorrectly assigns CD5 positivity to hairy cell leukemia instead of its actual CD103/CD25/CD11c profile. Hairy cell leukemia cells are CD5-NEGATIVE and characteristically express CD11c, CD25, CD103, and CD123, with TRAP (tartrate-resistant acid phosphatase) staining historically used for diagnosis.

Hairy cell leukemia (HCL) is a rare, indolent B-cell malignancy named for the irregular cytoplasmic projections visible on peripheral blood smear, and USMLE Step 1 tests it as a pattern-recognition vignette. The misconception that costs points: assigning CD5 positivity to HCL. CD5 belongs to CLL and mantle cell lymphoma; HCL is CD5-negative and instead expresses CD103, CD25, CD11c, and CD123. Getting those markers confused means misidentifying the disease on a flow cytometry question and likely choosing the wrong treatment (R-CHOP instead of cladribine). The classic patient is a middle-aged man with massive splenomegaly, pancytopenia, and a bone marrow that yields a dry tap.

The exam tests two main angles: recognition (what does it look like, what markers define it) and management (what do you treat it with, and what does the bone marrow biopsy show). The tricky part is that HCL has a specific immunophenotype that students frequently confuse with other B-cell malignancies. CD5 positivity belongs to CLL and mantle cell lymphoma — HCL is CD5-negative. HCL's signature markers are CD103, CD25, CD11c, and CD123. TRAP (tartrate-resistant acid phosphatase) staining was the historical gold standard and is still a high-yield factoid.

The other commonly missed detail is the 'dry tap' on bone marrow aspiration. HCL infiltrates the marrow and causes reticulin fibrosis, so you literally cannot aspirate cells — you get nothing, which is itself a diagnostic clue. Treatment is equally specific: cladribine (2-CDA), a purine analog, is first-line and produces durable remissions. Students who pattern-match 'aggressive B-cell disease = R-CHOP' will get this wrong. USMLE Step 1 rewards knowing that HCL is treated with a single agent, not a combination chemotherapy regimen.

From real student decks
57%have cards covering this topic
41%have mature cards

Common misconceptions

Common mistake
Wrong: Hairy cell leukemia is diagnosed primarily by flow cytometry showing CD5 positivity.
Right: Hairy cell leukemia cells are CD5-NEGATIVE and characteristically express CD11c, CD25, CD103, and CD123, with TRAP (tartrate-resistant acid phosphatase) staining historically used for diagnosis.
CD5 positivity is the hallmark of CLL and mantle cell lymphoma — assigning it to HCL is a common mix-up that costs points. HCL cells are CD5-negative and instead express a distinct cluster: CD103, CD25, CD11c, and CD123. TRAP staining (tartrate-resistant acid phosphatase) was the classic diagnostic test before flow cytometry became standard, and it remains a favorite Step 1 factoid because it's unique to HCL.
Common mistake
Gap: Missing that hairy cell leukemia causes marrow fibrosis leading to a dry tap on aspiration
Hairy cell leukemia causes extensive marrow fibrosis, resulting in a 'dry tap' on bone marrow aspiration, which is a classic diagnostic clue.
HCL cells infiltrate the bone marrow and trigger reticulin fibrosis, which replaces the normal loose marrow architecture with scar-like tissue. When you attempt aspiration, the fibrosis prevents cells from being withdrawn into the needle — you get a 'dry tap,' meaning no aspirate. This is a classic diagnostic clue in HCL vignettes and distinguishes it from diseases where marrow aspiration is informative.
Common mistake
Wrong: Hairy cell leukemia is treated with the same R-CHOP regimen used for aggressive B-cell lymphomas.
Right: First-line treatment for hairy cell leukemia is cladribine (2-CDA), a purine analog, which produces durable remissions in most patients.
R-CHOP is reserved for aggressive B-cell lymphomas like diffuse large B-cell lymphoma — it's not appropriate for indolent diseases like HCL. HCL responds extremely well to cladribine (2-CDA), a purine analog that induces durable complete remissions in most patients after a single course. Knowing that HCL is treated with one drug, not a multi-agent regimen, is the key management fact the exam expects.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Recognize the classic HCL presentation: middle-aged man with massive splenomegaly, pancytopenia, and hairy cytoplasmic projections on smear — and know the defining immunophenotype (CD103+, CD25+, CD11c+, CD123+, CD5-negative, TRAP-positive, BRAF V600E mutation).
  2. Know that bone marrow aspiration in HCL yields a 'dry tap' due to reticulin fibrosis, and that first-line treatment is cladribine (2-CDA), not R-CHOP or other combination regimens.

Can you avoid these mistakes?

A 55-year-old man presents with fatigue, splenomegaly, and pancytopenia. Peripheral smear shows lymphocytes with irregular cytoplasmic projections. Flow cytometry is ordered. Which CD markers would you expect to be positive, and which classic marker would be negative?
During workup of the same patient, a bone marrow biopsy is attempted and yields no aspirate. What is the pathologic explanation for this finding, and what is it called?
Your attending asks you to start treatment. You suggest R-CHOP because this is a B-cell malignancy. Why is this wrong, and what should first-line therapy actually be?
A vignette describes a patient with hairy cell leukemia and mentions BRAF V600E mutation. What is the significance of this mutation in HCL, and what targeted agent exploits it in relapsed or refractory disease?

Related topics

Leukemia vs Lymphoma Framework Hematopoiesis and Lineage Differentiation RBC Physiology and Lifespan WBC Differential and Function Platelet Physiology and Primary Hemostasis

See how your Anki deck covers this topic.

Upload your deck for a free audit →